Viral vector development is an important part of advancing cell and gene therapies, requiring specialized technologies and coordinated development and manufacturing capabilities. ProBio provides end-to-end CDMO services for adeno-associated virus (AAV) and lentiviral vector (LVV) programs, alongside capabilities in plasmid DNA development and manufacturing.
Supported by proprietary technologies and fast, integrated, globally compliant platforms, ProBio helps reduce development complexity and accelerate the progression of advanced therapy programs toward clinical stages. With expertise spanning early discovery through clinical development and commercial success, ProBio supports the advancement of AAV and LVV programs through integrated viral vector solutions.
Discover ProBio’s Advanced Viral Vector and Gene Therapy Solutions